ArticlePathogens & immunity2026
A Novel Adaptive Platform for Rapid, Simple Flow-Based Antibody Detection Devices Predicts NAb Levels to SARS-CoV-2.
Article in Pathogens & immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 has caused millions of deaths and continues to burden individuals and the healthcare system. Antibodies that neutralize SARS-CoV-2 have proven to be the most reliable markers of immune protection, targets for vaccine development, and approaches for anti-viral antibody-based therapies. Measuring neutralizing antibody (NAb) titers at the bedside could inform individualized shared decision-making with patients regarding the potential benefits of repeating vaccines, use of preventative or therapeutic antibody-based therapies, and, where relevant, collection of COVID-19 convalescent plasma (CCP) with greater efficacy, especially as NAb-escape mutations have guided SARS-CoV-2 variant emergence. However, specific and accessible assays to quantify NAb levels in individuals, including the identification of potential antibody donors at the time of donation, remain unavailable. Therefore, there is a need for platforms that can be rapidly adapted to quantify serum antibody responses with known or expected correlates of protection. Methods: In this report, we apply a novel semi-quantitative method to an established antibody lateral flow assay (sqLFA) and analyze its ability to detect the presence of functional NAbs in the serum of COVID-19-recovered individuals early in the pandemic. Results: We found that the sqLFA has a strong positive correlation with the gold-standard microneutralization assay (specificity 80% and sensitivity 90% at a microneutralization cutoff of 1:40). Conclusions: Taken together, the sqLFA provides a novel point-of-care-based platform for rapid readout of NAb-based immune protection to SARS-CoV-2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.